ABSTRACr A questionnaire was sent to physicians with an interest in chest disease to determine the dose and method of delivery of nebulised beta agonists in hospital. All of the 67 physicians replying gave beta agonists by nebuliser, and all reported either salbutamol (72%) or terbutaline (10%) as the drug they prescribed most commonly (18% gave either drug). There was a fivefold difference in the dose of salbutamol they prescribed most commonly (range 2-5-12-5 mg, mode 5 mg), a 20 fold difference in the volume of diluent solution used (range 0.5-10 ml, mode 2 ml), and a 10 fold variation in the flow rates of gas driving the nebuliser (range 1-10 I/min, mode 4 /min). There are therefore very large variations in the dose and method of delivery of beta agonists nebulised in hospital. Studies attempting to determine the optimum dose of beta agonist for use in a nebuliser need to take the type of nebuliser, diluent volume, and gas flow rate into account.
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Inhalation is the preferred route for administering beta agonists because of the lower incidence of side effects for a given degree of bronchodilatation. I2 The drug is usually delivered from a metered dose inhaler, though the use of nebulisers to administer beta agonists has increased recently in both hospital and domiciliary practice. The dose of beta agonist inhaled by the patient from a metered dose inhaler is about 10% of the dose administered,34 though it will be less if the inhaler is used incorrectly.5 With a nebuliser the proportion of the administered dose inhaled by the patient has varied from 1% to 12%.6-8 The proportion of drug inhaled from a nebuliser is likely to be more variable than that from a metered dose inhaler since it will depend on the type of nebuliser, diluent volume, and gas flow rate. We sent a questionnaire to 94 physicians to try to determine how much variation occurs in the way in which beta agonists are administered by nebuliser in hospital.
Method
A single sheet questionnaire with 14 questions (appendix) was sent in January 1982 to 94 physicians with an interest in chest disease in the United Kingdom. Physicians were randomly selected from the 1981 Thoracic Society handbook. The questionnaire was designed to determine: (1) how often the physicians used a nebuliser to deliver beta agonists; (2) which beta agonist they preferred and what dose was usually given; (3) the type of nebuliser they used most often and the way in which it was used.
Results
There were 67 replies, a 71 % response rate. All respondents used nebulisers to administer beta agonists in hospital. Fifty four (80%) prescribed nebulised beta agonists more than 10 times a month.
WHICH BETA AGONIST AND WHAT DOSE?
All physicians reported either salbutamol (5 mg/ml) or terbutaline (10 mg/ml) as the beta agonist they prescribed most commonly. Salbutamol was chosen by 48 (72%) respondents, terbutaline by seven Stainforth, Lewis C). Fifty four (81 %) continued nebulisation to "dryness"-that is, no further aerosol production by .). The dose most frequently prescribed was S the unit. When the nebuliser was used for a specific both salbutamol (43% salbutamol users) and time this ranged from 2 to 15 minutes &s, s-__ ..
terbutaline (61% terbutaline users).
The beta agonist was diluted in normal saline by 40 (60%) respondents and in water by 24 (35%). Three respondents used no diluent. Diluent volume ranged from 0-5 ml to 10 ml, with a mode of 2 ml (fig, B) .
The volume of diluent affects the amount of drug left in the residual volume-the volume remaining in the nebuliser after nebulisation to "dryness." Since this will alter the amount of drug given to the patient we calculated the effect of variation in dose and diluent volume for the 16 respondents giving salbutamol via the Inspiron Mini-Neb (residual volume 0*6 ml)-the most popular combination of nebuliser and beta agonist. The combined effect of the fourfold difference in dose and 20 fold difference in diluent volume used by these physicians resulted in an 11 fold variation in the estimated amount of drug leaving the nebuliser. Dosage and delivery of nebulised beta agonists in hospital mg, despite the fact that salbutamol is twice as potent as terbutaline.9 10 There was a fivefold difference between the smallest and the largest dose of salbutamol prescribed most commonly by different physicians and a fourfold difference in the case of terbutaline.
The volume of diluent used influences the amount of drug leaving the nebuliser by altering the amount of drug left in the residual volume. For example, if 5 mg salbutamol (1 ml) is given without diluent via an Inspiron Mini-Neb (residual volume 0-6 ml), only 2 mg will leave the nebuliser; if the same amount of salbutamol is diluted in 4 ml saline, twice as much drug will leave the nebuliser. Calculations based on subjects using the Mini-Neb and salbutamol showed an 11 fold variation in the estimated dose of drug leaving the nebuliser.
Many physicians used a gas flow rate of 4 I/min or less to drive the nebuliser yet high flow rates are necessary to comminute the liquid jet into droplets small enough to enter the airways-that is, a mass median diameter of around 10 ,um or less. With the Inspiron Mini-Neb, for example, particle size increases from a mass median diameter of 4 um at a flow rate of 8 I/min to 13 ,um at 4 l/min." The use of low flow rates may be due to concern over a possible reduction of hypoxic drive in hypercapnic patients. This problem is avoided by use of compressed air to drive the nebuliser.
Higher doses of beta agonist are recommended for use in nebulisers than in metered dose inhalers. The dose of salbutamol prescribed most commonly by our respondents (5 mg) is 25 times higher than the usual dose given by the metered dose inhaler (200 ,ug) and for terbutaline it is 10 times higher (5 mg and 500 ,ug respectively).
It has been suggested that nebulisers are less efficient than metered dose inhalers at delivering drugs to the lung but this will depend on the nebuliser and the way in which it is used. Deposition studies using the Inspiron Mini-Neb have shown that 12% of the drug leaving the nebuliser can be found in the lung8 compared with 8.8% from a metered dose inhaler.4 This is obviously important since airway response to a given dose of beta agonist is similar whether the drug is given by metered dose inhaler or nebuliser. '2 Few of the respondents monitored cardiac rhythm routinely during nebulisation and this presumably reflects confidence in the safety of nebulised beta agonists. In the study by Choo-Kang and Grant 10 mg of salbutamol given by intermittent positive pressure ventilation was effective and safe in patients with stable asthma. '3 The same has been true for subsequent studies of similar or smaner doses of salbutamol and terbutaline given by nebuliser to patients with both severe'41I and more stable chronic asthma.7 16 These studies were not designed, however, to detect infrequent complications such as arrhythmias and have often excluded patients with heart disease. Adverse cardiovascular effects from beta2 agonists are obviously uncommon, although angina has been reported'7 and we have seen supraventricular tachycardias after nebulised salbutamol. There is a large variation in the heart rate response to beta2 agonists'618 and some patients will be more susceptible to arrhythmias than others.
There is considerable variation in the way nebulisers are used to administer beta agonists in hospital practice and they are often used inefficiently. Efficiency could be improved by using optimum gas flow rates and diluent volumes. Improved efficiency will increase drug delivery to the lung but it may also increase side effects and the risk of arrythmias. We are not therefore recommending that efficiency should necessarily be improved until more is known about the optimum dose of beta agonists for general use in hospital when the age and medical condition of the patient are taken into account. This survey will allow physicians to see how the dose and method of administration of nebulised beta agonist that they use compare with the practice of other physicians. Studies designed to determine the optimal dose of beta agonists for patients in hospital and at home must specify the type of nebuliser used, flow rate, and diluent volume.
We are most grateful to the physicians who completed the questionnaire. 
